Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02316717




Registration number
NCT02316717
Ethics application status
Date submitted
6/11/2014
Date registered
15/12/2014
Date last updated
21/02/2020

Titles & IDs
Public title
A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis
Scientific title
A Phase ll, Randomized, Double-blind, Placebo-controlled Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis.
Secondary ID [1] 0 0
IMM-124E-2001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Non-alcoholic Steatohepatitis (NASH) 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Metabolic and Endocrine 0 0 0 0
Metabolic disorders
Diet and Nutrition 0 0 0 0
Obesity

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - IMM-124E
Other interventions - Placebo

Experimental: Treatment Arm A - IMM-124E, 600 mg three times daily, orally plus matching placebo

Experimental: Treatment Arm B - IMM-124E, 1200 mg three times daily, orally

Placebo comparator: Treatment Arm C - Matching placebo, three times daily, orally


Treatment: Other: IMM-124E
IMM-124E

Other interventions: Placebo
Matched placebo
Intervention code [1] 0 0
Treatment: Other
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Safety Outcome Measure
Timepoint [1] 0 0
24 Weeks
Primary outcome [2] 0 0
Percentage Fat Content of the Liver
Timepoint [2] 0 0
baseline and 24 weeks
Primary outcome [3] 0 0
Adverse Events
Timepoint [3] 0 0
24 weeks
Primary outcome [4] 0 0
Severity of Adverse Events
Timepoint [4] 0 0
24 weeks
Secondary outcome [1] 0 0
Systolic Blood Pressure
Timepoint [1] 0 0
baseline and 24 weeks
Secondary outcome [2] 0 0
Pulse Rate
Timepoint [2] 0 0
baseline and 24 weeks
Secondary outcome [3] 0 0
Diastolic Blood Pressure
Timepoint [3] 0 0
baseline and 24 weeks
Secondary outcome [4] 0 0
Respiratory Rate
Timepoint [4] 0 0
baseline and 24 weeks
Secondary outcome [5] 0 0
Serum Alanine Aminotransaminase (ALT)
Timepoint [5] 0 0
baseline and 24 weeks
Secondary outcome [6] 0 0
Peak Serum Concentration (Cmax)
Timepoint [6] 0 0
0, 4, 12 and 24 Weeks
Secondary outcome [7] 0 0
Minimum Serum Concentration (Cmin)
Timepoint [7] 0 0
0, 4, 12 and 24 Weeks
Secondary outcome [8] 0 0
Area Under the Concentration Time Curve (AUC)
Timepoint [8] 0 0
0, 4, 12 and 24 Weeks
Secondary outcome [9] 0 0
Elimination Half Life (T1/2)
Timepoint [9] 0 0
0, 4, 12 and 24 Weeks
Secondary outcome [10] 0 0
Body Mass Index (BMI)
Timepoint [10] 0 0
24 Weeks
Secondary outcome [11] 0 0
Waist Circumference
Timepoint [11] 0 0
24 Weeks
Secondary outcome [12] 0 0
Waist:Hip Ratio
Timepoint [12] 0 0
24 Weeks
Secondary outcome [13] 0 0
Hemoglobin (HB)A1C
Timepoint [13] 0 0
24 Weeks
Secondary outcome [14] 0 0
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)
Timepoint [14] 0 0
baseline and 24 Weeks
Secondary outcome [15] 0 0
Total Cholesterol
Timepoint [15] 0 0
24 Weeks
Secondary outcome [16] 0 0
Triglycerides
Timepoint [16] 0 0
24 Weeks
Secondary outcome [17] 0 0
Low Density Lipoprotein (LDL)
Timepoint [17] 0 0
24 Weeks
Secondary outcome [18] 0 0
High Density Lipoprotein (HDL)
Timepoint [18] 0 0
24 Weeks
Secondary outcome [19] 0 0
Serum Alanine Aminotransaminase (ALT)
Timepoint [19] 0 0
baseline to 24 weeks
Secondary outcome [20] 0 0
Serum Aspartate Aminotransaminase (AST)
Timepoint [20] 0 0
baseline to 24 Weeks
Secondary outcome [21] 0 0
Bilirubin
Timepoint [21] 0 0
baseline to 24 Weeks
Secondary outcome [22] 0 0
Albumin
Timepoint [22] 0 0
baseline to 24 Weeks
Secondary outcome [23] 0 0
Gamma Glutamyl Transpeptidase (GGT)
Timepoint [23] 0 0
baseline to 24 Weeks
Secondary outcome [24] 0 0
Serum Alanine Aminotransaminase (ALT)
Timepoint [24] 0 0
24 Weeks

Eligibility
Key inclusion criteria
1. Age = 18 years.
2. Provision of written informed consent.
3. Diagnosis of NASH, histologically proven within 12 months of Screening with

* NASH activity score (NAS) of 4 or more
* cytologic ballooning score of at least 1;
* 10% or more macrovescicular steatosis.
* Hematoxylin & Eosin (H&E) stained slides and/or paraffin block available for independent assessment.
4. HBA1C of <9.0
5. Agree to the use of effective contraceptive measures if either male or female of child bearing potential.
Minimum age
18 Years
Maximum age
99 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Presence of vascular liver disease or cirrhosis;
2. Presence of liver disease with other cause (autoimmune, metabolic, medication induced);
3. BMI <25 kg/m^2;
4. Alcohol use >30 g/day;
5. Type 1 diabetes;
6. 6. History of major bariatric surgery (not including balloon / sleeve gastrectomy);
7. Weight loss or gain of 5kg or more in the past 6 months or >10% change in bodyweight in the past 12 months;
8. Contraindication for MRI;
9. Inadequate venous access;
10. Lactating/breastfeeding/pregnant at Screening or Baseline;
11. HIV antibody positive, hepatitis B surface antigen positive (HBsAg) or Hepatitis C virus (HCV)-RNA positive;
12. Receiving an elemental diet or parenteral nutrition;
13. Concurrent conditions

* Inflammatory bowel disease;
* Unstable angina, myocardial infarction, transient ischemic events, or stroke within 24 weeks of Screening;
* Ongoing infectious, ongoing multi-systemic immune-mediated and/or concurrent or past malignant disease;
* Any other concurrent condition which, in the opinion of the investigator, could impact adversely on the subject participating or on the interpretation of the study data;
14. Concurrent medications including:

* anti-NASH therapy(s) taken for more than 10 continuous days in the last 3 months. These include S-adenosyl methionine (SAM-e), betaine, milk thistle, probiotic supplements (other than yoghurt), vitamin E and gemfibrozil.

* NB: If vitamin E or gemfibrozil are used, the dose must be stable and liver biopsy confirming diagnosis of NASH subsequent to commencing treatment; commencing treatment;
* Wash out for any of the anti-NASH therapies is as follows: under 10 days no washout required, more than 10 days and up to 3 months treatment requires 6 weeks washout. Any treatment of over 3 months would require to re-biopsy to ensure histological eligibility
* thiazolidinediones (glitazones), dipeptidyl peptidase 4 inhibitors (gliptins) or glucagon-like peptide-1 analogs in the last 6 months. If treatment commenced and is stable for more than 6 month prior to the determinant biopsy and the dose is still stable at time of study entry, subjects will be eligible for recruitment.
* Allowable anti-diabetic treatment includes metformin and/or sulfonylureas administered at constant dose for at least 2 months prior to study entry.
* Subjects treated with Insulin are eligible if clinically stable on insulin treatment (i.e. no recurrent acute hypo-/hyperglycemic episodes diagnosed clinically and by Glucose serum levels of <50 mg/dL and >200 mg/dL respectively) for at least 2 months prior to study entry.
* immune modulatory agents including

* In the last 3 months:
* systemic steroids for more than 7 days.
* daily treatment with multiple non-steroidal anti-inflammatory drugs (such as aspirin >100mg/day, ibuprofen, naproxen, meloxicam, celecoxib) for more than 1 month within 3 months prior to study entry;
* In the last 12 months:
* azathioprine, 6-mercaptopurine, methotrexate, cyclosporin, anti-TNFa therapies (infliximab, adalimumab, etanercept) or anti-integrin therapies (namixilab) ;
* more than 10 consecutive days oral or parenteral antibiotics within 4 weeks prior to study entry (Note: such subjects would not be included in the stool and PBMC analysis).
* variable dose of antilipidemic agents (3-hydroxy-3-methyl-glutaryl (HMG)-Co-A reductase inhibitors - "statins") in the 3 months prior to study entry.
15. The following laboratory abnormalities:

* Neutrophil count =1.0 x 10^9/L
* Platelets <100 x 10^9/L
* Hemoglobin <10 g/dL
* Albumin <3.5 g/dL
* International Normalized Ratio (INR) >1.5
* Total bilirubin >1.5 x upper limit of reference range (unless Gilbert's syndrome or extrahepatic source as denoted by increased indirect bilirubin fraction)
* Either creatinine clearance =60 mL/minute calculated by Cockroft Gault or creatinine >1.5x upper limit of reference range.
16. Known substance abuse, including inhaled or injected drugs in the year prior to Screening.
17. Cow milk allergy, lactose intolerance or any known or suspected hypersensitivity to study products.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/12/2014
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
30/10/2017
Sample size
Target
Accrual to date
Final
133
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC
Recruitment hospital [1] 0 0
The Nepean Hospital - Penrith
Recruitment hospital [2] 0 0
Westmead Hospital - Westmead
Recruitment hospital [3] 0 0
Princess Alexandra Hospital - Woolloongabba
Recruitment hospital [4] 0 0
Box Hill Hospital - Box Hill
Recruitment hospital [5] 0 0
Royal Melbourne Hospital - Parkville
Recruitment hospital [6] 0 0
The Alfred Hospital - Prahran
Recruitment postcode(s) [1] 0 0
2750 - Penrith
Recruitment postcode(s) [2] 0 0
2145 - Westmead
Recruitment postcode(s) [3] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [4] 0 0
3128 - Box Hill
Recruitment postcode(s) [5] 0 0
3050 - Parkville
Recruitment postcode(s) [6] 0 0
3004 - Prahran
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Illinois
Country [5] 0 0
United States of America
State/province [5] 0 0
Missouri
Country [6] 0 0
United States of America
State/province [6] 0 0
North Carolina
Country [7] 0 0
United States of America
State/province [7] 0 0
Ohio
Country [8] 0 0
United States of America
State/province [8] 0 0
Texas
Country [9] 0 0
United States of America
State/province [9] 0 0
Virginia
Country [10] 0 0
United States of America
State/province [10] 0 0
Washington
Country [11] 0 0
Israel
State/province [11] 0 0
Jerusalem
Country [12] 0 0
Israel
State/province [12] 0 0
Tel Aviv

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Immuron Ltd.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study will evaluate the safety and preliminary efficacy of two dose levels of IMM-124E in reducing liver fat and/or serum alanine aminotransaminase (ALT) compared with placebo.
Trial website
https://clinicaltrials.gov/study/NCT02316717
Trial related presentations / publications
Jin L, Sun Y, Li Y, Zhang H, Yu W, Li Y, Xin Y, Alsareii SA, Wang Q, Zhang D. A synthetic peptide AWRK6 ameliorates metabolic associated fatty liver disease: involvement of lipid and glucose homeostasis. Peptides. 2021 Sep;143:170597. doi: 10.1016/j.peptides.2021.170597. Epub 2021 Jun 10.
Public notes

Contacts
Principal investigator
Name 0 0
Dan Peres
Address 0 0
Immuron Ltd.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02316717